Please Wait
Applying Filters...
menu
    • menu
    FDA’s landmark approvals of BMS’ schizo med, Madrigal’s MASH drug, US$ 16.5 bn Catalent buyout make it to top 10 news of 2024

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Nov 2024: Trump’s HHS pick drags down jab makers’ stocks; Novartis, Merck, Roche ink billion-dollar deals

    Stock Recap
    #PipelineProspector

    Menu

    Cytarabine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,519Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Certificate Holder Certificate No. Substance Issue Date Status Type End Date Substance No.
    30/12/2024 Archimica
    Italy
    		 ARCHIMICA S.P.A Lodi IT CEP 2023-289 - Rev 00 Cytarabine, Process 2 2024-02-06 Valid Chemical 760
    30/12/2024 Archimica
    Italy
    		 ARCHIMICA S.P.A Lodi IT R1-CEP 2000-048 - Rev 04 Cytarabine 2020-10-16 Valid Chemical 760